389819945-NANDA-I-2018-2020-pt-es-pdf

pharmacotherapy. In: Neonatal therapy: An update. New York, NY: Excerpta Medica
1986;122–146 Finnegan LP. Neonatal
abstinence syndrome: assessment and
pharmacotherapy. In: Nelson N, ed. Current therapy in neonatal-perinatal medicine. 2nd ed.
Ontario: BC Decker; 1990
Galinkin J, Koh JL, Committee on Drugs, Section On Anesthesiology and Pain Medicine,
American Academy of Pediatrics. Recognition and management of iatrogenically induced
opioid dependence and withdrawal in children. Pediatrics. 2014; 133 (1):152–155
Hudak ML, Tan RC, COMMITTEE ON DRUGS, COMMITTEE ON FETUS AND
NEWBORN, American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics.
2012; 129(2):e540–e560
Jansson LM, Velez ML. Infants of drug-dependent mothers. Pediatr Rev. 2011; 32(1): 5–12,
quiz 12–13
Kirchner L, Graf-Rohrmeister K, Klebermass-Schrehof K, et al. Neonatal abstinence
syndrome in European and North American neonates: differences in clinical
characteristics derived from a prospective randomized trial. Klin Padiatr. 2014;
226(5): 274–280
Orlando S. An overview of clinical tools used to assess neonatal abstinence syndrome. J Perinat
Neonatal Nurs. 2014; 28(3):212–219
Patel P, Abdel-Latif ME, Hazelton B, et al. Perinatal outcomes of Australian
buprenorphine-exposed mothers and their newborn infants. J Paediatr Child Health. 2013;
49 (9):746–753
Serane VT, Kurian O. Neonatal abstinence syndrome. Indian J Pediatr. 2008; 75(9): 911–914
Welle-Strand GK, Skurtveit S, Jones HE, et al. Neonatal outcomes following in utero exposure
to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of
Pregnant Women in Norway from 1996 to
2009. Drug Alcohol Depend. 2013; 127(1–3):200–206
Zimmermann-Baer U, Nötzli U, Rentsch K, Bucher HU. Finnegan neonatal abstinence scoring
system: normal values for first 3 days and weeks 5–6 in